Investing Ideas
/
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Results

0 new

Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.

2 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
	9926 Akeso	HK$73.25	7.6%	54.4%	HK$63.1b	HK$72.16	PS32.6x	E53.3%	n/a
	2268 WuXi XDC Cayman	HK$26.40	1.0%	-5.4%	HK$31.6b	HK$30.02	PE49.5x	E27.5%	n/a

Page 1 of 1